DigiPath, Inc. engages in the provision of cannabis testing, education, training, and news coverage. It operates through the Digipath Labs and The National Marijuana News Corp. business units. The Digipath Labs business unit focuses on testing all forms of cannabis-based products using FDA-compliant laboratory equipment and proprietary standard operating procedures. The National Marijuana News Corp. business unit provides news, interviews, and education on all cannabis. The company was founded by Todd Denkin on October 5, 2010 and is headquartered in Las Vegas, NV.
Industry, Sector and Symbol
Industry Medical Specialties
Sub-IndustryCannabis
SectorMedical
Phone(702) 527-2060
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.84 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable
Digipath (OTCMKTS:DIGP) Frequently Asked Questions
What is Digipath's stock symbol?
Digipath trades on the OTCMKTS under the ticker symbol "DIGP."
How were Digipath's earnings last quarter?
Digipath Inc (OTCMKTS:DIGP) announced its earnings results on Tuesday, May, 15th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.58 million for the quarter. Digipath had a negative return on equity of 185.07% and a negative net margin of 81.93%. View Digipath's Earnings History.
When is Digipath's next earnings date?
Has Digipath been receiving favorable news coverage?
Media stories about DIGP stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Digipath earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Digipath's key competitors?
Some companies that are related to Digipath include DiaMedica Therapeutics (DMAC), Oncomed Pharmaceuticals (OMED), TSO3 (TOS), Amryt Pharma (AMYT), ImmuCell (ICCC), Novoheart (NVH), Fuse Medical (FZMD), Microbot Medical (MBOT), Restoration Robotics (HAIR), Caladrius Biosciences (CLBS), DiaMedica Therapeutics (DMA), Moleculin Biotech (MBRX), ProPhase Labs (PRPH), Achaogen (AKAO) and Universal Biosensors (UBI).
What other stocks do shareholders of Digipath own?
Who are Digipath's key executives?
Digipath's management team includes the folowing people:
- Todd Denkin, Chairman, President & Chief Executive Officer
- Todd A. Peterson, Chief Financial Officer, Secretary & Treasurer
- Cindy Orser, Director & Chief Science Officer
How do I buy shares of Digipath?
Shares of DIGP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Digipath's stock price today?
One share of DIGP stock can currently be purchased for approximately $0.2290.
How big of a company is Digipath?
Digipath has a market capitalization of $10.02 million and generates $2.84 million in revenue each year.
What is Digipath's official website?
How can I contact Digipath?
Digipath's mailing address is 6450 CAMERON STREET SUITE 113, LAS VEGAS NV, 89118. The company can be reached via phone at (702) 527-2060.
MarketBeat Community Rating for Digipath (OTCMKTS DIGP)
MarketBeat's community ratings are surveys of what our community members think about Digipath and other stocks. Vote "Outperform" if you believe DIGP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DIGP will underperform the S&P 500 over the long term. You may vote once every thirty days.
